Streetbeat News

Products Services

ATRA

Atara Biotherapeutics announced that it expects its cash runway to extend into 2027, which will support key pipeline readouts. The company plans to initiate a trial for ATA3219 in Systemic Lupus Erythematosus in the fourth quarter, with initial data expected by mid-2025.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 9:17 pm

ACB

TLRY

Germany's cannabis market is growing rapidly, with Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis Inc. (NASDAQ:ACB), and Demecan emerging as key players in domestic cultivation. The market is projected to reach €1.7 billion ($1.86 billion) by 2025. These companies are strategically positioned to capitalize on the increasing demand for medical cannabis in Germany.

Portfolio Pulse from Javier Hasse

August 12, 2024 | 8:55 pm

AVAV

CW

HII

ITA

LMT

NOC

USO

Oil prices surged to $79.60 per barrel amid Middle East tensions, with the US deploying military assets to the region. Defense stocks, including Curtiss-Wright, Huntington Ingalls, Northrop Grumman, AeroVironment, and Lockheed Martin, saw gains.

Portfolio Pulse from Piero Cingari

August 12, 2024 | 8:52 pm

BZFD

BuzzFeed, Inc. (NASDAQ:BZFD) shares surged nearly 30% after the company reported better-than-expected Q3 results. Despite a 24.51% decrease in sales year-over-year, the company showed a significant improvement in quarterly losses and highlighted growth in commerce and affiliate revenues. CEO Jonah Peretti emphasized the benefits of their investment in AI technology. BuzzFeed expects Q4 revenues between $58 million and $68 million and adjusted EBITDA between $6 million and $11 million.

Portfolio Pulse from Erica Kollmann

August 12, 2024 | 8:42 pm

WBD

Kit Harington, known for his role as Jon Snow in Warner Bros. Discovery Inc's HBO series 'Game of Thrones,' discussed the controversial ending of the show, attributing it to the exhaustion of the cast and crew. Despite the mixed reactions, Harington was open to a spin-off centered on Jon Snow, which was eventually scrapped.

Portfolio Pulse from Franca Quarneti

August 12, 2024 | 8:34 pm

TNDM

Tandem Diabetes Care has provided an update on the March recall of its t:connect Mobile App for iOS devices, citing continued issues with insulin pump shutdowns due to battery depletion. The company plans to release a new app version to address these issues. There have been 107 confirmed adverse events, including two hospitalizations.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:33 pm

KYTX

Kyverna Therapeutics shares are trading higher after the company received U.S. FDA RMAT designation for KYV-101 in the treatment of progressive myasthenia gravis.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:25 pm

OCX

Oncocyte has published a case series demonstrating the effectiveness of its VitaGraft Kidney diagnostic test in monitoring antibody-mediated rejection in kidney transplant patients treated with anti-CD38 therapy.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:24 pm

SYRS

Syros Pharmaceuticals will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial due to disappointing interim results. The trial was evaluating a triplet regimen of tamibarotene with venetoclax and azacitidine compared to a doublet regimen in AML patients. The decision follows a futility analysis showing similar response rates between the two treatment arms.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:23 pm

LCID

Lucid Group (NASDAQ:LCID) is set to begin production of its Gravity SUV in late 2024, featuring both Tesla NACS and CCS charging ports. This dual-port system offers more charging options for users. Lucid's technology advancements and partnerships, including one with Aston Martin, are highlighted. Despite these developments, Lucid's stock is down 30% year-to-date.

Portfolio Pulse from Chris Katje

August 12, 2024 | 8:17 pm